FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895099432> ?p ?o ?g. }

• W2895099432 endingPage "767" @default.
• W2895099432 startingPage "761" @default.
• W2895099432 abstract "Development of an effective and safe anti-cancer drug is an urgent request for hepatocellular carcinoma (HCC). In this study, we synthesized a series of novel indole substituted dihydropyrido[2,3-d]pyrimidines through the multicomponent reactions to connect pyrido[2,3-d]pyrimidine and indole moities via an one-pot three-component reaction of 3-cyanoacetyl indoles 1, various aromatic aldehyde 2, and 2,6-diaminopyrimidin-4(3H)-one 3. Subsequently, we screened their cytotoxicity via CCK-8 assay in HepG2 cells, a human hepatoma cell line and chose compound 4p that showed the lowest dosage of IC50 to study the antitumor activities to HCC. Interestingly, 4p significantly induced the cell cycle arrest and apoptosis of HepG2 via targeting AKT and ERK1/2 signaling pathways in vitro. To improve the solubility of compound 4p, we hosted this compound into the substituted glucopyranose ring of (2-Hydroxypropyl)-β-cyclodextrin (HBC), a cosolvent approved by FDA with the help of ultrasonication and heating. Finally, we showed that oral administration of HBC-hosted 4p effectively inhibited tumor growth and prolonged the survival time of tumor-bearing mice in subcutaneously xenografted model. These results suggest that multicomponent reactions connecting pyrido[2,3-d]pyrimidine and indole moities is a productive and economical method for the synthesis of anticancer compound, and oral administration of HBC-hosted 4p is an effective and safe agents for treatment of HCC, whose clinical application potency warrant further studies." @default.
• W2895099432 created "2018-10-12" @default.
• W2895099432 creator A5016594599 @default.
• W2895099432 creator A5016727969 @default.
• W2895099432 creator A5021389505 @default.
• W2895099432 creator A5027934348 @default.
• W2895099432 creator A5069991290 @default.
• W2895099432 creator A5070294470 @default.
• W2895099432 creator A5075234643 @default.
• W2895099432 date "2018-11-01" @default.
• W2895099432 modified "2023-10-17" @default.
• W2895099432 title "Oral administration of indole substituted dipyrido[2,3-d]pyrimidine derivative exhibits anti-tumor activity via inhibiting AKT and ERK1/2 on hepatocellular carcinoma" @default.
• W2895099432 cites W1965239527 @default.
• W2895099432 cites W1971837077 @default.
• W2895099432 cites W1984264526 @default.
• W2895099432 cites W1985075123 @default.
• W2895099432 cites W1993118022 @default.
• W2895099432 cites W2008757142 @default.
• W2895099432 cites W2011147083 @default.
• W2895099432 cites W2014613601 @default.
• W2895099432 cites W2019365183 @default.
• W2895099432 cites W2045497341 @default.
• W2895099432 cites W2046024621 @default.
• W2895099432 cites W2058388078 @default.
• W2895099432 cites W2063478572 @default.
• W2895099432 cites W2073001877 @default.
• W2895099432 cites W2074305443 @default.
• W2895099432 cites W2078686890 @default.
• W2895099432 cites W2102418869 @default.
• W2895099432 cites W2107495112 @default.
• W2895099432 cites W2133190342 @default.
• W2895099432 cites W2150026213 @default.
• W2895099432 cites W2157300001 @default.
• W2895099432 cites W2162083881 @default.
• W2895099432 cites W2328579942 @default.
• W2895099432 cites W2340948639 @default.
• W2895099432 cites W2588466167 @default.
• W2895099432 cites W2730945377 @default.
• W2895099432 cites W2793577044 @default.
• W2895099432 cites W4211105405 @default.
• W2895099432 cites W4230603486 @default.
• W2895099432 cites W4245403358 @default.
• W2895099432 doi "https://doi.org/10.1016/j.bbrc.2018.09.120" @default.
• W2895099432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30293685" @default.
• W2895099432 hasPublicationYear "2018" @default.
• W2895099432 type Work @default.
• W2895099432 sameAs 2895099432 @default.
• W2895099432 citedByCount "14" @default.
• W2895099432 countsByYear W28950994322019 @default.
• W2895099432 countsByYear W28950994322020 @default.
• W2895099432 countsByYear W28950994322021 @default.
• W2895099432 countsByYear W28950994322022 @default.
• W2895099432 countsByYear W28950994322023 @default.
• W2895099432 crossrefType "journal-article" @default.
• W2895099432 hasAuthorship W2895099432A5016594599 @default.
• W2895099432 hasAuthorship W2895099432A5016727969 @default.
• W2895099432 hasAuthorship W2895099432A5021389505 @default.
• W2895099432 hasAuthorship W2895099432A5027934348 @default.
• W2895099432 hasAuthorship W2895099432A5069991290 @default.
• W2895099432 hasAuthorship W2895099432A5070294470 @default.
• W2895099432 hasAuthorship W2895099432A5075234643 @default.
• W2895099432 hasConcept C185592680 @default.
• W2895099432 hasConcept C190283241 @default.
• W2895099432 hasConcept C192527728 @default.
• W2895099432 hasConcept C202751555 @default.
• W2895099432 hasConcept C2778019345 @default.
• W2895099432 hasConcept C2779321679 @default.
• W2895099432 hasConcept C502942594 @default.
• W2895099432 hasConcept C55493867 @default.
• W2895099432 hasConcept C57992300 @default.
• W2895099432 hasConcept C62112901 @default.
• W2895099432 hasConcept C71240020 @default.
• W2895099432 hasConcept C71924100 @default.
• W2895099432 hasConcept C75217442 @default.
• W2895099432 hasConcept C98274493 @default.
• W2895099432 hasConceptScore W2895099432C185592680 @default.
• W2895099432 hasConceptScore W2895099432C190283241 @default.
• W2895099432 hasConceptScore W2895099432C192527728 @default.
• W2895099432 hasConceptScore W2895099432C202751555 @default.
• W2895099432 hasConceptScore W2895099432C2778019345 @default.
• W2895099432 hasConceptScore W2895099432C2779321679 @default.
• W2895099432 hasConceptScore W2895099432C502942594 @default.
• W2895099432 hasConceptScore W2895099432C55493867 @default.
• W2895099432 hasConceptScore W2895099432C57992300 @default.
• W2895099432 hasConceptScore W2895099432C62112901 @default.
• W2895099432 hasConceptScore W2895099432C71240020 @default.
• W2895099432 hasConceptScore W2895099432C71924100 @default.
• W2895099432 hasConceptScore W2895099432C75217442 @default.
• W2895099432 hasConceptScore W2895099432C98274493 @default.
• W2895099432 hasFunder F4320313574 @default.
• W2895099432 hasFunder F4320321001 @default.
• W2895099432 hasFunder F4320321543 @default.
• W2895099432 hasFunder F4320321605 @default.
• W2895099432 hasFunder F4320322769 @default.
• W2895099432 hasIssue "3" @default.
• W2895099432 hasLocation W28950994321 @default.
• W2895099432 hasLocation W28950994322 @default.
• W2895099432 hasOpenAccess W2895099432 @default.

• next